Epidemiology & Risk Factors

  • Most common inherited retinal dystrophy; onset in childhood to young adulthood.
  • Progressive hereditary dystrophy of the retina or of the photoreceptors and the retinal pigment epithelium
  • Inheritance: AD, AR, or XL (most severe).
  • Syndromic associations:
    • Usher syndrome: RP + congenital sensorineural hearing loss.
    • Bardet-Biedl syndrome: RP + obesity, polydactyly, hypogonadism, renal anomalies.

Clinical Features

  • Symptoms:
    • Nyctalopia (night blindness): Earliest presentation (rod degeneration). c
    • Progressive visual field loss: Concentric peripheral constriction (“tunnel vision”). Central vision lost late.
  • Fundoscopic Triad: c
    • “Bone-spicule” pigment deposits (mid-periphery).
    • Attenuated retinal arterioles.
    • Waxy pallor of the optic disc.

Diagnosis

  • Initial: Dilated fundoscopy (classic triad) + Visual field perimetry (symmetric ring scotoma/constriction).
  • Confirmatory / Gold Standard: Electroretinography (ERG) (reduced a- and b-wave amplitudes; rods extinguished before cones).
  • Adjunctive:
    • OCT: Assesses photoreceptor loss and detects cystoid macular edema (CME).
    • Genetic testing: Evaluates for targetable mutations (e.g., RPE65).

Differential Diagnostics

  • Open-Angle Glaucoma: Diff by optic disc cupping (↑ cup-to-disc ratio), elevated IOP, absence of bone spicules.
  • Hydroxychloroquine Retinopathy: Diff by drug exposure history, “bull’s-eye” maculopathy, primarily central/paracentral defects.
  • Vitamin A Deficiency: Diff by Bitot spots (conjunctival plaques), xerophthalmia; reversible with repletion. c

Management

  • Targeted: Voretigene neparvovec (gene therapy) for confirmed biallelic RPE65 mutations.
  • Supportive: UV-blocking sunglasses, low-vision aids, mobility training, genetic counseling.
  • Secondary Complications:
    • CME: Carbonic anhydrase inhibitors (oral acetazolamide or topical dorzolamide).
    • Cataracts: Surgical lens extraction with IOL placement.

Complications

  • Cystoid macular edema (CME) (leading treatable cause of acute visual acuity decline).
  • Posterior subcapsular cataracts.
  • Legal blindness (visual field ≤ 20° or visual acuity ≤ 20/200).